{
    "clinical_study": {
        "@rank": "74017", 
        "arm_group": [
            {
                "arm_group_label": "Apremilast 40 mg", 
                "arm_group_type": "Experimental", 
                "description": "40 mg Apremilast orally BID for 24 weeks"
            }, 
            {
                "arm_group_label": "Apremilast 30 mg", 
                "arm_group_type": "Experimental", 
                "description": "30 mg Apremilast orally BID for 24 weeks"
            }, 
            {
                "arm_group_label": "Placebo + Apremilast 40 mg", 
                "arm_group_type": "Experimental", 
                "description": "Placebo orally BID for 12 weeks, followed by Apremilast 40 mg BID for 12 weeks"
            }, 
            {
                "arm_group_label": "Placebo + Apremilast 30 mg", 
                "arm_group_type": "Experimental", 
                "description": "Placebo orally BID for 12 weeks, followed by Apremilast 30 mg BID for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with\n      moderate to severe atopic dermatitis"
        }, 
        "brief_title": "Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Dermatitis, Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males or females, aged \u2265 18 years (\u2265 20 for Japanese subjects) at the time of\n             consent.\n\n          2. Have a diagnosis of atopic dermatitis for \u2265 12 months.\n\n          3. Have moderate to severe atopic dermatitis which is considered inappropriate for\n             topical therapy or which cannot be adequately controlled by topical therapy.\n\n          4. Meet the laboratory criteria as defined per protocol\n\n          5. Females of Childbearing Potential (FCBP) must have a negative pregnancy test at\n             Screening and Baseline. Sexually active FCBP must use one of the approved\n             contraceptive options required per protocol while on and for at least 28 days after\n             the last dose of study medication\n\n          6. Male subjects (including those who have had a vasectomy) who engage in activity in\n             which conception is possible must use barrier contraception while on and for at least\n             28 days after the last dose of study medication.\n\n        Exclusion Criteria:\n\n          1. Active tuberculosis (TB) or a history of inadequately treated tuberculosis.\n\n          2. Positive for hepatitis B surface antigen or hepatitis C antibody\n\n          3. Pregnant or breast feeding\n\n          4. History of allergy to any component of the study medication.\n\n          5. Active skin infection requiring systemic antimicrobials at Baseline."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "189", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087943", 
            "org_study_id": "CC-10004-AD-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Apremilast 40 mg", 
                    "Placebo + Apremilast 40 mg"
                ], 
                "description": "Orally twice a day (BID)", 
                "intervention_name": "Apremilast", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CC-10004", 
                    "Otezla"
                ]
            }, 
            {
                "arm_group_label": [
                    "Apremilast 30 mg", 
                    "Placebo + Apremilast 30 mg"
                ], 
                "description": "Orally twice a day (BID)", 
                "intervention_name": "Apremilast", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CC-10004", 
                    "Otezla"
                ]
            }, 
            {
                "arm_group_label": "Placebo + Apremilast 40 mg", 
                "description": "Orally twice a day (BID)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + Apremilast 30 mg", 
                "description": "Orally twice a day (BID)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Thalidomide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Atopic Dermatitis", 
            "Atopic Eczema"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Atopic Dermatitis", 
        "overall_contact": {
            "email": "clinicaltrialdisclosure@celgene.com", 
            "last_name": "Associate Director Clinical Trial Disclosure", 
            "phone": "1-888-260-1599"
        }, 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Yufang Lu, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The percentage change from Baseline in the EASI score at week 12. The EASI is a composite scoring system assessed by the investigator based on the the four body regions (head and neck, upper limbs, lower limbs, and trunk) affected with Atopic Dermatitis (AD) and the intensities of key signs of AD (erythema, induration/papulation,excoriation, and lichenification). The total EASI score ranges from 0 to 72.", 
            "measure": "Eczema Area and Severity Index (EASI) Score", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087943"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Type, frequency and severity of adverse events, and relationship of adverse events to the investigational product", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 weeks"
            }, 
            {
                "description": "The proportion of subjects who achieve at least a 50% reduction from Baseline in the EASI score at Week 12. The EASI is a composite scoring system assessed by the investigator based on the the four body regions (head and neck, upper limbs, lower limbs, and trunk) affected with AD and the intensities of key signs of AD (erythema, induration/papulation,excoriation, and lichenification). The total EASI score ranges from 0 to 72.", 
                "measure": "EASI Score", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "The percentage change from Baseline in the average weekly pruritus NRS score at Week 4. Pruritus is the cardinal symptom of Atopic Dermatits. Pruritus at night may result in sleep disturbance. The severity of pruritus and sleep quality will be assessed by subjects via a diary using a numeric rating scale ranging from 0 to 10.", 
                "measure": "Pruritus Numeric Rating Scale (NRS)", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}